-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Antibody drug conjugates(ADC) cancer therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Track & Monitor
Immuno-oncology in pharma: neoepitope prediction
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s neoepitope prediction segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FKPC-101 in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FKPC-101 in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FKPC-101 in Metastatic Prostate Cancer Drug Details: FK-PC101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RiMO-301 in Recurrent Head And Neck Squamous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NC-762 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NC-762 in Non-Small Cell Lung Cancer Drug Details: NC-762 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Systemic Sclerosis (Scleroderma) Drug Details: efzofitimod (ATYR-1923) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirpiglenastat in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirpiglenastat in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirpiglenastat in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: DRP-104 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SB-11285 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SB-11285 in Non-Small Cell Lung Cancer Drug Details: SB-11285 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SB-11285 in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SB-11285 in Merkel Cell Carcinoma Drug Details: SB-11285 is under development...